Chinese COVID-19 vaccine approved for clinical trials

A subunit vaccine gainst COVID-19 created by experts from the Academy of Military Medical Sciences (China) was approved for clinical trials.

A subunit vaccine is a type of vaccine that contains only a fragment of the pathogen to stimulate a protective immune response, according to the World Health Organization (WHO). It is considered safer and more stable than live-attenuated vaccines, which contain a weakened version of the live pathogen, but it may not elicit as strong a protection as live-attenuated versions.

The vaccine has been approved for safety, efficacy and quality by a third party. In this way, according to the Chinese clinical trial registration database, a Phase 1 trial that will examine whether the experimental vaccine is safe in humans aims to recruit 108 healthy people to participate in the process between March 16 and December 31.

The drug has been conceived by a military medical research team led by People’s Army epidemiologist and division general Chen Wei, who traveled to Wuhan City, the focus of the epidemic, to work on a vaccine in collaboration with the biotechnology company CanSino Biologics based in the northern city of Taijin. Dr. Chen Wei is a well-known researcher for her studies on Severe Acute Respiratory Syndrome (SARS) related coronavirus (SARS-CoV-1) and Ebola viruses ―she developed in 2014 the first vaccine in Asia and the third in the world to fight the Ebola virus―. In fact, part of the work was based on the study of existing Ebola vaccines.

Editorial Disclaimer: information published during the 2020 COVID-19 pandemic may be updated frequently to reflect the dynamic nature of current understanding.

Related Posts

Social Media